All in all I’m sure that ANP will still be putting ATL1102 forward for both MS and DMD. They still haven’t looked at what the potency of ATL1102 on MS would be at a higher dosage. It too may prove to be groundbreaking. Plus I think ANP is a little further down the road in relation to development and testing than Monash, and they are cashed up fairly well too. I’m sure ANP will be following this story closely being a Melbourne based company. GLTAH.
MS Cure - Monash Uni, page-13
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $69.41M | |||
| Open | High | Low | Value | Volume |
| 7.9¢ | 7.9¢ | 7.6¢ | $26.62K | 343.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 113467 | 7.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.7¢ | 98248 | 1 |
View Market Depth
| Last trade - 16.10pm 06/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.7¢ |
Change
0.000 ( 1.28 %) |
||||
| Open | High | Low | Volume | ||
| 7.9¢ | 7.9¢ | 7.7¢ | 14800 | ||
| Last updated 15.52pm 06/05/2024 ? | |||||
| PER (ASX) Chart |